RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Rosetta Genomics Stock

Rosetta Genomics Net Income 2025

Rosetta Genomics Net Income

-25.79 M USD

Ticker

ROSGQ

ISIN

IL0011026494

WKN

A0MMDG

In 2025, Rosetta Genomics's profit amounted to -25.79 M USD, a 32.71% increase from the -19.43 M USD profit recorded in the previous year.

The Rosetta Genomics Net Income history

YEARNET INCOME (undefined USD)
2018e-
2017e-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-
2004-
2003-

Rosetta Genomics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Rosetta Genomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Rosetta Genomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Rosetta Genomics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Rosetta Genomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Rosetta Genomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Rosetta Genomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Rosetta Genomics’s growth potential.

Rosetta Genomics Revenue, EBIT and net profit per share

DateRosetta Genomics RevenueRosetta Genomics EBITRosetta Genomics Net Income
2018e39.46 M undefined-15.09 M undefined-25.79 M undefined
2017e20.13 M undefined-14.98 M undefined-19.43 M undefined
20169.23 M undefined-15.66 M undefined-16.23 M undefined
20158.27 M undefined-15.88 M undefined-17.35 M undefined
20141.33 M undefined-14.25 M undefined-14.53 M undefined
2013405,000 undefined-13.35 M undefined-12.9 M undefined
2012201,000 undefined-8.27 M undefined-10.46 M undefined
2011103,000 undefined-8.78 M undefined-8.83 M undefined
2010280,000 undefined-15.11 M undefined-14.76 M undefined
2009150,000 undefined-14.8 M undefined-16.51 M undefined
20081.51 M undefined-14.04 M undefined-9.46 M undefined
20070 undefined-11.04 M undefined-14.66 M undefined
20060 undefined-8.15 M undefined-7.61 M undefined
20050 undefined-5.18 M undefined-5.84 M undefined
20040 undefined-2.98 M undefined-2.98 M undefined
20030 undefined-2.35 M undefined-2.31 M undefined

Rosetta Genomics stock margins

The Rosetta Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Rosetta Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Rosetta Genomics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Rosetta Genomics's sales revenue. A higher gross margin percentage indicates that the Rosetta Genomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Rosetta Genomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Rosetta Genomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Rosetta Genomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Rosetta Genomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Rosetta Genomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Rosetta Genomics Margin History

Rosetta Genomics Gross marginRosetta Genomics Profit marginRosetta Genomics EBIT marginRosetta Genomics Profit margin
2018e19.44 %-38.23 %-65.34 %
2017e19.44 %-74.41 %-96.51 %
201619.44 %-169.63 %-175.8 %
201524.14 %-192.02 %-209.78 %
20141.28 %-1,074 %-1,094.65 %
2013-75.06 %-3,295.56 %-3,184.44 %
2012-28.36 %-4,112.94 %-5,202.49 %
2011-214.56 %-8,521.36 %-8,572.82 %
2010-125 %-5,396.43 %-5,271.43 %
2009-126.67 %-9,866.67 %-11,006.67 %
200849.01 %-929.8 %-626.49 %
200719.44 %0 %0 %
200619.44 %0 %0 %
200519.44 %0 %0 %
200419.44 %0 %0 %
200319.44 %0 %0 %

Rosetta Genomics Aktienanalyse

What does Rosetta Genomics do?

Rosetta Genomics Ltd is a company specializing in personalized medicine, focused on the development and commercialization of diagnostic tests based on RNA interference and NGS technologies for cancer diseases. The company was founded in 2000 and has its headquarters in Israel, with offices in the USA and Europe. The history of Rosetta Genomics began with the development of MicroRNA (miRNA), RNA molecules that act as regulators of gene expression in cells. The company developed a technology that allows for the identification of specific miRNAs that are characteristic of different types of cancers. As a result, Rosetta Genomics started developing a series of diagnostic tests based on these miRNAs to enable personalized therapy for cancer patients. Rosetta Genomics' business model is based on the commercialization of diagnostic tests for various cancer types. These tests can be requested by doctors and other medical professionals to determine the best treatment for patients. The company works closely with clinicians and researchers to continually improve its tests and stay up to date with the latest technology. The company operates in two main divisions: RosettaGX and RosettaWGX. RosettaGX offers diagnostic tests for various cancer types, including lung cancer, thyroid cancer, and colorectal cancer. These tests utilize Rosetta Genomics' proprietary RNA interference technology to identify specific miRNAs indicative of a particular type of cancer. On the other hand, RosettaWGX offers NGS services that allow researchers and pharmaceutical companies to collect and analyze DNA sequencing data to gain insights into the genetics of cancer. Some of the products offered by Rosetta Genomics include the miRview® Lung Test, miRview® mets2 Test, and miRview® Thyroid Test. The miRview® Lung Test identifies specific miRNAs characteristic of various types of lung tumors to enable an accurate diagnosis. The miRview® mets2 Test can determine the origin of cancer cells that have spread from the primary site, enabling targeted treatment. The miRview® Thyroid Test enables an accurate diagnosis of thyroid cancer and can determine the likelihood of a more aggressive form of the disease. Overall, Rosetta Genomics has developed a wide range of diagnostic tests and services based on a unique technology platform to enable personalized medicine for cancer patients. The company collaborates closely with doctors, researchers, and pharmaceutical companies to continually improve its tests and stay at the forefront of technology. With its innovative products and services, Rosetta Genomics is an important player in the field of personalized medicine and contributes to improving treatment outcomes for cancer patients. Rosetta Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Rosetta Genomics's Profit Margins

The profit margins of Rosetta Genomics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Rosetta Genomics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Rosetta Genomics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Rosetta Genomics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Rosetta Genomics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Rosetta Genomics stock

How much profit has Rosetta Genomics made this year?

Rosetta Genomics has made -25.79 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 32.71% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Rosetta Genomics publish its earnings?

Rosetta Genomics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Rosetta Genomics?

The profits of Rosetta Genomics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Rosetta Genomics?

You can learn more about the earnings of Rosetta Genomics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Rosetta Genomics pay?

Over the past 12 months, Rosetta Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Rosetta Genomics is expected to pay a dividend of 0 USD.

What is the dividend yield of Rosetta Genomics?

The current dividend yield of Rosetta Genomics is .

When does Rosetta Genomics pay dividends?

Rosetta Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Rosetta Genomics?

Rosetta Genomics paid dividends every year for the past 0 years.

What is the dividend of Rosetta Genomics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Rosetta Genomics located?

Rosetta Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Rosetta Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Rosetta Genomics from 7/27/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/27/2025.

When did Rosetta Genomics pay the last dividend?

The last dividend was paid out on 7/27/2025.

What was the dividend of Rosetta Genomics in the year 2024?

In the year 2024, Rosetta Genomics distributed 0 USD as dividends.

In which currency does Rosetta Genomics pay out the dividend?

The dividends of Rosetta Genomics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Rosetta Genomics

Our stock analysis for Rosetta Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Rosetta Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.